-Melanocyte–Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models

UNLABELLED The purpose of this study was to examine the therapeutic efficacy of (188)Re-(Arg(11))[Cys(3,4,10),d-Phe(7)]alpha-melanocyte-stimulating hormone(3-13) (CCMSH) in the B16/F1 murine melanoma- and TXM13 human melanoma-bearing mouse models. METHODS (Arg(11))CCMSH was synthesized and labeled with (188)Re to form (188)Re-(Arg(11))CCMSH. B16/F1 melanoma-bearing mice were administrated 7.4 MBq, 22.2 MBq, and 2 x 14.8 MBq of (188)Re-(Arg(11))CCMSH via the tail vein. TXM13 melanoma-bearing mice were separately injected with 22.2 MBq, 2 x 14.8 MBq, and 37.0 MBq of (188)Re-(Arg(11))CCMSH through the tail vein. Two groups of 10 mice bearing either B16/F1 or TXM13 tumors were injected with saline as untreated controls. RESULTS In contrast to the untreated control group, (188)Re-(Arg(11))CCMSH yielded rapid and lasting therapeutic effects in the treatment groups with either B16/F1 or TXM13 tumors. The tumor growth rate was reduced and the survival rate was prolonged in the treatment groups. Treatment with 2 x 14.8 MBq of (188)Re-(Arg(11))CCMSH significantly extended the mean life of B16/F1 tumor mice (P < 0.05), whereas the mean life of TXM13 tumor mice was significantly prolonged after treatment with 22.2-MBq and 37.0- MBq doses of (188)Re-(Arg(11))CCMSH (P < 0.05). High-dose (188)Re-(Arg(11))CCMSH produced no observed normal tissue toxicity. CONCLUSION The therapy study results revealed that (188)Re-(Arg(11))CCMSH yielded significant therapeutic effects in both B16/F1 murine melanoma- and TXM13 human melanoma-bearing mouse models. (188)Re-(Arg(11))CCMSH appears to be a promising radiolabeled peptide for targeted radionuclide therapy of melanoma.

[1]  C. Hoefnagel.  Radionuclide therapy revisited , 2005, European Journal of Nuclear Medicine.

[2]  M. Béhé,et al.  DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy , 1997, European Journal of Nuclear Medicine.

[3]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[4]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[5]  T. Quinn,et al.  Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. , 2003, Bioconjugate chemistry.

[6]  A. Eberle,et al.  A Novel DOTA-α-Melanocyte–Stimulating Hormone Analog for Metastatic Melanoma Diagnosis , 2002 .

[7]  T. Quinn,et al.  In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy , 2002, International journal of cancer.

[8]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  L. Kvols,et al.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. , 2002, Seminars in nuclear medicine.

[10]  M. Cremonesi,et al.  Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group , 2002 .

[11]  T. Visser,et al.  Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  B. Bernard,et al.  [177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy , 2001, International journal of cancer.

[13]  F. Orsi,et al.  Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide , 2001, European Journal of Nuclear Medicine.

[14]  S. Jurisson,et al.  Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. , 2000, Cancer research.

[15]  A. Eberle,et al.  Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.

[16]  P. Cutler,et al.  Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  P. Cutler,et al.  Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  S. Jurisson,et al.  Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Mueller‐Brand,et al.  Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.

[20]  S. Jurisson,et al.  Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. , 1997, Bioconjugate chemistry.

[21]  H. Biersack,et al.  Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. , 1997, Anticancer research.

[22]  M. Zalutsky,et al.  Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue , 1997 .

[23]  P. Schubiger,et al.  Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. , 1996, Bioconjugate chemistry.

[24]  A. Marghoob,et al.  Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications , 1995, Cancer.

[25]  A. Eberle,et al.  [111In]‐DTPA‐labeled analogues of α‐melanocyte‐stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo , 1994, International journal of cancer.

[26]  B. Beatty,et al.  Application of the cross‐organ beta dose method for tissue dosimetry in tumor‐bearing mice treated with a 90y‐labeled immunoconjugate , 1994, Cancer.

[27]  B. Beatty,et al.  A mouse model for calculating cross‐organ beta doses from yttrium‐90‐labeled immunoconjugates , 1994, Cancer.

[28]  V. Hruby,et al.  Design, Synthesis, and Conformation of Superpotent and Prolonged Acting Melanotropins a , 1993, Annals of the New York Academy of Sciences.

[29]  T. Maughan,et al.  The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. , 1992, The British journal of radiology.

[30]  T. Visser,et al.  [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. , 1991, Life sciences.

[31]  W A Volkert,et al.  Therapeutic radionuclides: production and decay property considerations. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  C. G. Knight,et al.  A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. , 1990, British Journal of Cancer.

[33]  A. Eberle,et al.  Characterization of Receptors for α-Melanocyte-stimulating Hormone on Human Melanoma Cells , 1989 .

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  J. B. Tatro,et al.  Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. , 1987, Endocrinology.

[36]  B. Shapiro,et al.  Radionuclide diagnosis and therapy of thyroid cancer: current status report. , 1985, Seminars in nuclear medicine.